1
40
4
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1002/hed.23647" target="_blank" rel="noreferrer noopener">http://doi.org/10.1002/hed.23647</a>
Pages
644–649
Issue
5
Volume
37
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Phase II study of gefitinib in patients with advanced salivary gland cancers.
Publisher
An entity responsible for making the resource available
Head & neck
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-05
Subject
The topic of the resource
80 and over; Adenocarcinoma/drug therapy/mortality/pathology; adenoid cystic carcinoma; Adenoid Cystic/*drug therapy/mortality/pathology; Adult; Aged; Antineoplastic Agents/*therapeutic use; Carcinoma; Disease-Free Survival; Dose-Response Relationship; Drug; Drug Administration Schedule; Female; gefitinib; Gefitinib; Humans; Local/*drug therapy/mortality/pathology; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness/pathology; Neoplasm Recurrence; Neoplasm Staging; non-adenoid cystic carcinoma; Prognosis; Quinazolines/*therapeutic use; Remission Induction; response to therapy; salivary gland cancer; Salivary Gland Neoplasms/*drug therapy/mortality/pathology; Survival Analysis; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Jakob John A; Kies Merrill S; Glisson Bonnie S; Kupferman Michael E; Liu Diane D; Lee J Jack; El-Naggar Adel K; Gonzalez-Angulo Ana M; Blumenschein George R Jr
Description
An account of the resource
BACKGROUND: The purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. METHODS: We conducted a phase II study in adenoid cystic carcinoma (ACC) and non-ACC. Gefitinib was administered 250 mg orally daily. The primary endpoint was tumor response. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and disease control rates. EGFR and human epidermal growth factor receptor 2 (HER2) expression were evaluated and correlated with outcomes. RESULTS: Thirty-seven patients were enrolled in this study, and 36 were evaluable (18 with ACC and 18 with non-ACC). No responses were observed. Median PFS was 4.3 months and 2.1 months, and median OS was 25.9 months and 16 months for patients with ACC and non-ACC, respectively. The disease control rate at 8 weeks was higher in patients with ACC. No unexpected toxicities occurred. EGFR and HER2 overexpression did not correlate with outcomes. CONCLUSION: We did not observe significant clinical activity of gefitinib in advanced salivary gland cancer. NCT00509002.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/hed.23647" target="_blank" rel="noreferrer noopener">10.1002/hed.23647</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
80 and over
Adenocarcinoma/drug therapy/mortality/pathology
adenoid cystic carcinoma
Adenoid Cystic/*drug therapy/mortality/pathology
Adult
Aged
Antineoplastic Agents/*therapeutic use
Blumenschein George R Jr
Carcinoma
Department of Internal Medicine
Disease-Free Survival
Dose-Response Relationship
Drug
Drug Administration Schedule
El-Naggar Adel K
Female
Gefitinib
Glisson Bonnie S
Gonzalez-Angulo Ana M
Head & neck
Humans
Jakob John A
Kies Merrill S
Kupferman Michael E
Lee J Jack
Liu Diane D
Local/*drug therapy/mortality/pathology
Male
Maximum Tolerated Dose
Middle Aged
NEOMED College of Medicine
Neoplasm Invasiveness/pathology
Neoplasm Recurrence
Neoplasm Staging
non-adenoid cystic carcinoma
Prognosis
Quinazolines/*therapeutic use
Remission Induction
response to therapy
salivary gland cancer
Salivary Gland Neoplasms/*drug therapy/mortality/pathology
Survival Analysis
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1371/journal.pone.0085010" target="_blank" rel="noreferrer noopener">http://doi.org/10.1371/journal.pone.0085010</a>
Pages
e85010–e85010
Issue
1
Volume
9
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Generation of "virtual" control groups for single arm prostate cancer adjuvant trials.
Publisher
An entity responsible for making the resource available
PloS one
Date
A point or period of time associated with an event in the lifecycle of the resource
2014
1905-07
Subject
The topic of the resource
Humans; Male; Middle Aged; Aged; Treatment Outcome; Disease-Free Survival; *Nomograms; *Prostatectomy; Antineoplastic Agents/therapeutic use; Control Groups; Controlled Clinical Trials as Topic; Prostate/drug effects/pathology/surgery; Prostatic Neoplasms/*drug therapy/mortality/pathology/surgery; Neoplasm Recurrence; Chemotherapy; Adjuvant/*methods; Local/*drug therapy/mortality/pathology/surgery
Creator
An entity primarily responsible for making the resource
Jia Zhenyu; Lilly Michael B; Koziol James A; Chen Xin; Xia Xiao-Qin; Wang Yipeng; Skarecky Douglas; Sutton Manuel; Sawyers Anne; Ruckle Herbert; Carpenter Philip M; Wang-Rodriguez Jessica; Jiang Jun; Deng Mingsen; Pan Cong; Zhu Jian-Guo; McLaren Christine E; Gurley Michael J; Lee Chung; McClelland Michael; Ahlering Thomas; Kattan Michael W; Mercola Dan
Description
An account of the resource
It is difficult to construct a control group for trials of adjuvant therapy (Rx) of prostate cancer after radical prostatectomy (RP) due to ethical issues and patient acceptance. We utilized 8 curve-fitting models to estimate the time to 60%, 65%, ... 95% chance of progression free survival (PFS) based on the data derived from Kattan post-RP nomogram. The 8 models were systematically applied to a training set of 153 post-RP cases without adjuvant Rx to develop 8 subsets of cases (reference case sets) whose observed PFS times were most accurately predicted by each model. To prepare a virtual control group for a single-arm adjuvant Rx trial, we first select the optimal model for the trial cases based on the minimum weighted Euclidean distance between the trial case set and the reference case set in terms of clinical features, and then compare the virtual PFS times calculated by the optimum model with the observed PFSs of the trial cases by the logrank test. The method was validated using an independent dataset of 155 post-RP patients without adjuvant Rx. We then applied the method to patients on a Phase II trial of adjuvant chemo-hormonal Rx post RP, which indicated that the adjuvant Rx is highly effective in prolonging PFS after RP in patients at high risk for prostate cancer recurrence. The method can accurately generate control groups for single-arm, post-RP adjuvant Rx trials for prostate cancer, facilitating development of new therapeutic strategies.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1371/journal.pone.0085010" target="_blank" rel="noreferrer noopener">10.1371/journal.pone.0085010</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Nomograms
*Prostatectomy
2014
Adjuvant/*methods
Aged
Ahlering Thomas
Antineoplastic Agents/therapeutic use
Carpenter Philip M
Chemotherapy
Chen Xin
Control Groups
Controlled Clinical Trials as Topic
Deng Mingsen
Disease-Free Survival
Gurley Michael J
Humans
Jia Zhenyu
Jiang Jun
Kattan Michael W
Koziol James A
Lee Chung
Lilly Michael B
Local/*drug therapy/mortality/pathology/surgery
Male
McClelland Michael
McLaren Christine E
Mercola Dan
Middle Aged
Neoplasm Recurrence
Pan Cong
PloS one
Prostate/drug effects/pathology/surgery
Prostatic Neoplasms/*drug therapy/mortality/pathology/surgery
Ruckle Herbert
Sawyers Anne
Skarecky Douglas
Sutton Manuel
Treatment Outcome
Wang Yipeng
Wang-Rodriguez Jessica
Xia Xiao-Qin
Zhu Jian-Guo
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1634/theoncologist.10-90002-9" target="_blank" rel="noreferrer noopener">http://doi.org/10.1634/theoncologist.10-90002-9</a>
Pages
9–17
Volume
10 Suppl 2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Can we approach zero relapse in breast cancer?
Publisher
An entity responsible for making the resource available
The oncologist
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-10
Subject
The topic of the resource
Female; Humans; Gene Expression Profiling; Prognosis; Recurrence; Disease-Free Survival; Lymph Nodes/pathology; Neoadjuvant Therapy; Aromatase Inhibitors/therapeutic use; Breast Neoplasms/mortality/pathology/*prevention & control/*therapy; Antineoplastic Agents; Adjuvant; Chemotherapy; Hormonal/*therapeutic use
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P
Description
An account of the resource
Adjuvant hormonal therapy and adjuvant chemotherapy have contributed significantly to the falling rates of breast cancer mortality. The introduction of taxanes and aromatase inhibitors in the adjuvant setting represents recent important improvements. More recently, the demonstration of significant benefit in the adjuvant setting with novel molecular targeted therapies (such as trastuzumab [Herceptin; Genentech, Inc., South San Francisco, CA, http://www.gene.com]) is already beginning to have a substantial impact on the adjuvant treatment of patients with certain tumor characteristics (i.e., HER-2 positivity). Neoadjuvant treatment represents an approach that offers an intermediate end point (i.e., pathologic complete response) that can be used as a marker of therapeutic activity. Furthermore, the use of genomic profiling is starting to replace the traditional prognostic and predictive factors currently used to estimate risks for recurrence and response to particular adjuvant therapies. These recent developments have demonstrated that the notion of approaching zero relapse in breast cancer patients is now within our reach.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1634/theoncologist.10-90002-9" target="_blank" rel="noreferrer noopener">10.1634/theoncologist.10-90002-9</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2005
Adjuvant
Antineoplastic Agents
Aromatase Inhibitors/therapeutic use
Breast Neoplasms/mortality/pathology/*prevention & control/*therapy
Chemotherapy
Disease-Free Survival
Female
Gene Expression Profiling
Hormonal/*therapeutic use
Humans
Lymph Nodes/pathology
Mamounas Eleftherios P
Neoadjuvant Therapy
Prognosis
Recurrence
The oncologist
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1097/COC.0000000000000250" target="_blank" rel="noreferrer noopener">http://doi.org/10.1097/COC.0000000000000250</a>
Pages
90–91
Issue
1
Volume
39
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Regional Nodal Irradiation: Examining the Clinical Implications of Randomized Trials.
Publisher
An entity responsible for making the resource available
American journal of clinical oncology
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-02
Subject
The topic of the resource
*Randomized Controlled Trials as Topic; Adjuvant/adverse effects/methods; Axilla; Breast Neoplasms/pathology/*radiotherapy; Disease-Free Survival; Female; Humans; Lymph Nodes/*pathology; Lymphatic Irradiation/adverse effects/*methods; Lymphedema/etiology; Mastectomy; Radiation Pneumonitis/etiology; Radiotherapy; Survival Rate
Creator
An entity primarily responsible for making the resource
Shah Chirag; Khan Atif; Arthur Douglas; Wazer David; Mantz Constantine; Verma Vivek; Vicini Frank
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1097/COC.0000000000000250" target="_blank" rel="noreferrer noopener">10.1097/COC.0000000000000250</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Randomized Controlled Trials as Topic
2016
Adjuvant/adverse effects/methods
American journal of clinical oncology
Arthur Douglas
Axilla
Breast Neoplasms/pathology/*radiotherapy
Disease-Free Survival
Female
Humans
Khan Atif
Lymph Nodes/*pathology
Lymphatic Irradiation/adverse effects/*methods
Lymphedema/etiology
Mantz Constantine
Mastectomy
Radiation Pneumonitis/etiology
Radiotherapy
Shah Chirag
Survival Rate
Verma Vivek
Vicini Frank
Wazer David